Ligand PharmaceuticalsLGND

那斯達克 · USD
183.13
-0.90
(-0.49%)
收盤 12/12 04:59 (UTC+8)
12/12 04:59 (UTC+8)

財務數據

損益表

loading
載入中...
icon
  • 0.26
  • 0.33
  • 0.28
  • 0.31
  • 0.42
  • 0.52
  • 0.43
  • 0.45
  • 0.48
  • 1.15
icon
  • -40.05
  • 24.66
  • -14.50
  • 10.24
  • 34.07
  • 24.76
  • -17.37
  • 5.89
  • 5.06
  • 142.43
  • icon
    營業收入(億)
  • icon
    季增長率(%)
單位:美元千元
年季
2025/Q3
2025/Q2
2025/Q1
2024/Q4
2024/Q3
2024/Q2
2024/Q1
2023/Q4
2023/Q3
2023/Q2
營業收入淨額
115,461
47,627
45,333
42,812
51,812
41,531
30,978
28,101
32,868
26,366
營業成本
3,8012,9074,8492,8372,4492,9062,8821,6413,4851,669
營業毛利
111,660
44,720
40,484
39,975
49,363
38,625
28,096
26,460
29,383
24,697
營業費用
56,72936,27676,70049,612--25,10829,81828,42626,680
研發費用
21,0196,56750,0854,4255,6755,3545,9715,4885,5326,854
推銷及管理費用
27,61321,45118,35832,84832,28717,62310,95115,99214,65611,287
非經常性項目費用
---4,081-26,491----
其他營業費用
8,0978,2588,2578,2588,2588,2578,1868,3388,2388,539
營業利益
54,931
8,444
-36,216
-9,637
3,143
-19,100
2,988
-5,479
3,078
-1,983
其他收入及費用
11,2293,932-13,097-63,281-8,739-45,020110,60020,586-13,1005,438
利息費用
9101,1538678837431,2701411311284
稅前純益
141,137
11,223
-50,180
-39,200
-6,339
-65,390
113,447
17,097
-12,144
3,171
所得稅
23,8646,376-7,729-8,112833-13,47927,308-1,091-1,871881
稅後純益
117,273
4,847
-42,451
-31,088
-7,172
-51,911
86,139
18,188
-10,273
2,290
基本每股稅後盈餘(元)
5.990.25-2.21-1.64-0.39-2.884.861.04-0.740.13
稀釋每股稅後盈餘(元)
5.680.24-2.21-1.68-0.41-2.884.751.03-0.570.15
基本平均股數(千股)
19578.0019327.0019191.0018974.0018419.0018028.0017732.0017466.0017380.0017276.00
稀釋平均股數(千股)
20629.0019926.0019191.0018974.0018419.0018028.0018122.0017676.0017380.0017730.00
還原基本每股稅後盈餘(元)
5.990.25-2.21-1.64-0.39-2.884.861.04-0.740.13
還原稀釋每股稅後盈餘(元)
5.680.24-2.21-1.68-0.41-2.884.751.03-0.570.15
還原基本平均股數(千股)
19,57819,32719,19118,97418,41918,02817,73217,46617,38017,276
還原稀釋平均股數(千股)
20,62919,92619,19118,97418,41918,02818,12217,67617,38017,730
EBITDA(千元)
149,90420,669-40,675-29,5533,967-55,097122,75825,471-4,36012,273

大家都在看

HOT